drugset
drugset / Trial / NCT00871273

Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma

NCT00871273 ↗

Phase 4 Terminated 13 enrolled Cambridge University Hospitals NHS Foundation Trust
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) of capecitabine in patients who have undergone a total gastrectomy.

Timeline

Start
2009-11
Primary completion
2013-10
Completion
2014-10

Outcome

Outcome not reported

Stopped (Enrollment): “1\. Slow recruitment; 2. Change to clinical environment reducing the pool of potentially eligible patients; 3. Availability of data from another similar study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 625 mg/m2 Oral
Subject Capecitabine Small molecule 1250 mg/m2 Oral

Indications

gastric adenocarcinoma